

1 **Title:** Arresting Vertical Transmission of Hepatitis B Virus (AVERT-HBV) in the Democratic  
2 Republic of the Congo

3  
4 **Authors:** Peyton Thompson MD,<sup>1</sup> Camille E. Morgan,<sup>2\*</sup> Patrick Ngimbi MD,<sup>3\*</sup> Kashamuka  
5 Mwandagalirwa MPH,<sup>3</sup> Noro Ravelomanana,<sup>3</sup> Martine Tabala,<sup>3</sup> Malongo Fathy,<sup>3</sup> Bienvenu  
6 Kawende,<sup>3</sup> Jérémie Muwonga,<sup>4</sup> Pacifique Misingi,<sup>5</sup> Charles Mbendi MD,<sup>6</sup> Christophe Luhata  
7 MD,<sup>7</sup> Ravi Jhaveri MD,<sup>8</sup> Gavin Cloherty PhD,<sup>9</sup> Didine Kaba PhD,<sup>3</sup> Marcel Yotebieng PhD,<sup>10</sup>  
8 and Jonathan B. Parr MD<sup>11</sup>

9  
10 <sup>1</sup>Division of Infectious Diseases, Department of Pediatrics, University of North Carolina, Chapel  
11 Hill; <sup>2</sup>Department of Epidemiology, Gillings School of Global Public Health, University of  
12 North Carolina, Chapel Hill; <sup>3</sup>Kinshasa School of Public Health, and <sup>4</sup>National AIDS Control  
13 Program, and <sup>5</sup>National Blood Transfusion Program, and <sup>6</sup>Department of Gastroenterology,  
14 University Hospital, and <sup>7</sup>Expanded Programme on Immunisation, Kinshasa, Democratic  
15 Republic of Congo; <sup>8</sup>Department of Pediatrics, Division of Infectious Diseases, Northwestern  
16 University Feinberg School of Medicine, Chicago, Illinois; <sup>9</sup>Abbott Laboratories, Abbott Park,  
17 Illinois; <sup>10</sup>Division of General Internal Medicine, Department of Medicine, Albert Einstein  
18 College of Medicine; and <sup>11</sup>Division of Infectious Diseases, Department of Medicine, University  
19 of North Carolina, Chapel Hill.

20 \* Co-second authors.

21  
22 **Corresponding Author:** Peyton Thompson, MD, MSCR; CB #7036, University of North  
23 Carolina School of Medicine, Chapel Hill, NC 27599; Peyton\_Thompson@med.unc.edu; Phone  
24 919-445-0854, Fax 919-966-7277

25  
26 **Abstract Word Count:** 242

27  
28 **Manuscript Word Count:** 3,500

29  
30 **Tables and Figures:** 4 Figures, 1 Table

31  
32 **Supplementary Material:** 1 Figure, 3 Tables

33

34 **ABSTRACT**

35 **Background:** Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite  
36 the widespread availability of effective vaccines. We evaluated the feasibility of adding HBV  
37 testing and treatment of pregnant women and birth-dose vaccination of HBV-exposed infants to  
38 the HIV prevention of MTCT (PMTCT) program infrastructure in the Democratic Republic of  
39 the Congo (DRC), where HBV treatment and birth-dose vaccination programs are not  
40 established.

41 **Methods:** As part of the HIV PMTCT program at two maternity centers in Kinshasa, DRC,  
42 pregnant women were screened for HBV at routine prenatal care registration. Pregnant women  
43 with high viral load and/or HBeAg positivity were offered tenofovir disoproxil fumarate (TDF).  
44 HBV-exposed infants received a birth-dose of HBV vaccine within 24 hours of life. The primary  
45 endpoint was the feasibility and acceptability of the study.

46 **Findings:** Of 4,016 women screened, 109 (2.7%) were HBsAg-positive. Ten of 91 (11.1%)  
47 women evaluated had high-risk disease. Of 88 infants, 60 (68.2%) received a birth-dose vaccine;  
48 of these, 46 (76.7%) received a timely birth-dose. No cases of HBV MTCT were observed in our  
49 cohort. There were no serious adverse events associated with TDF nor with birth-dose vaccine.  
50 The study procedures were highly acceptable (>80%) among mothers.

51 **Interpretation:** Adding HBV screening and treatment of pregnant women and infant birth-dose  
52 vaccination to existing HIV PMTCT platforms is feasible in countries like the DRC. Birth-dose  
53 vaccination against HBV integrated within the current Expanded Programme on Immunization  
54 (EPI) and HIV PMTCT program could accelerate progress toward HBV elimination in Africa.

55

56 **Funding:** This project was supported by a Gillings Innovation Laboratory award funded by the  
57 2007 Gillings Gift to UNC-Chapel Hill’s Gillings School of Global Public Health. Existing  
58 infrastructure from an NIH R01HD087993 grant was leveraged for this project.

59 **Keywords:** hepatitis B virus, mother-to-child transmission, birth-dose vaccination, Democratic  
60 Republic of the Congo

61

62 **Abbreviations:**

63	ALT	Alanine aminotransferase
64	AST	Aspartate aminotransferase
65	DBS	Dried Blood Spot
66	DRC	Democratic Republic of the Congo
67	HBeAg	Hepatitis B envelop Antigen
68	HBsAg	Hepatitis B surface Antigen
69	HBV	Hepatitis B Virus
70	MTCT	Mother-to-child Transmission
71	PMTCT	Prevention of Mother-to-child Transmission
72	SSA	Sub-Saharan Africa
73	TDF	Tenofovir Disoproxil Fumarate

74

75 **INTRODUCTION**

76 Viral hepatitis is a leading infectious killer globally, with hepatitis B virus (HBV) alone  
77 accounting for nearly one million deaths annually.<sup>1</sup> Despite the existence of an effective vaccine,  
78 the prevalence of HBV in sub-Saharan Africa (SSA) remains unacceptably high. Mother-to-child  
79 transmission (MTCT) is a silent driver of the HBV epidemic. In the absence of any intervention,  
80 70% to 90% of mothers with high-risk HBV (defined as a viral load  $\geq$  200,000 IU/mL and/or  
81 HBV “e” antigen [HBeAg] positivity) will transmit the virus to their infants, compared to 10% to  
82 40% of mothers who are HBeAg-negative.<sup>2</sup> The World Health Organization (WHO)  
83 recommends that all infants receive a birth-dose of HBV vaccine as soon as possible after birth,  
84 preferably within 24 hours, followed by at least two additional vaccine doses.<sup>3</sup> The three-dose  
85 series provides  $\geq$ 95% protection against HBV infection, but breakthrough transmission can occur  
86 despite vaccination in infants born to women with high-risk HBV.<sup>4,5</sup> In its 2020 guidelines on  
87 HBV prevention of MTCT (PMTCT), the WHO recommends that HBV-infected women with  
88 high-risk HBV receive antiviral prophylaxis from the 28<sup>th</sup> week of pregnancy until or beyond  
89 delivery to prevent breakthrough MTCT.<sup>3,6,7</sup> Most HIV-HBV co-infected women receive  
90 tenofovir as part of their antiretroviral regimen. However, the feasibility of providing antiviral  
91 prophylaxis for HBV mono-infected pregnant women in low-resource settings in SSA has yet to  
92 be tested.

93

94 The prevalence of HBV in the Democratic Republic of the Congo (DRC) is 3.3%, with high  
95 (2.2%) prevalence among children under age five, which correlates to approximately 450,000  
96 Congolese children living with chronic HBV, and at risk for liver disease and premature death.<sup>8,9</sup>  
97 While HBV vaccine has been part of the DRC’s Expanded Program on Immunization (EPI) since

98 2007,<sup>10</sup> the first dose is not administered until six weeks of life, which is too late for the  
99 prevention of peri-partum MTCT. Similarly, there are no screening programs to identify and  
100 treat pregnant women with high-risk HBV, despite established infrastructure for the HIV  
101 PMTCT. The EPI delivers other birth-dose vaccines (BCG and polio), and so can be leveraged  
102 alongside the HIV PMTCT infrastructure to both deliver the birth-dose HBV vaccine and to  
103 screen and treat women with high-risk HBV.<sup>11,12</sup>

104

105 In this study, we assessed the feasibility of building upon existing EPI and HIV PMTCT  
106 infrastructures in Kinshasa, DRC to deliver HBV birth-dose vaccine and to identify and treat  
107 HBV-infected pregnant women at high risk of MTCT according to WHO guidelines.

108

## 109 **MATERIALS AND METHODS**

### 110 *Study Setting and Design*

111 This demonstration project was implemented in the two largest maternity centers in Kinshasa:  
112 Binza and Kingasani (both private/not-for-profit clinics). The two facilities were chosen not only  
113 because of their size, but also because of their long-standing collaborations with our HIV  
114 PMTCT team. In collaboration with the Expanded Program on Immunization (EPI), the required  
115 monovalent vaccine doses were acquired and stored within the existing cold chain system. We  
116 leveraged the infrastructure of an ongoing randomized trial of continuous quality interventions  
117 on long-term ART outcomes among pregnant/postpartum women in Kinshasa (CQI-PMTCT  
118 study, NCT03048669), through which we were already screening HIV-infected pregnant women  
119 for Hepatitis B and C.<sup>13,14</sup>

### 120 *Study Population and Procedures*

121 Between September 24, 2018 and February 22, 2019, all pregnant women registering for  
122 prenatal services at either of the two clinics were provided group counseling on HBV and  
123 PMTCT thereof, and were invited to be screened for HBV. Those who verbally agreed were  
124 screened using point-of-care ALERE DETERMINE HBsAg testing (Abbott Diagnostics, Abbott  
125 Park, Illinois). Pregnant women who tested positive were referred for evaluation and inclusion in  
126 this feasibility study. To be eligible for prospective follow-up, pregnant women who screened  
127 HbsAg-positive needed to meet the following additional criteria: 1) gestational age  $\leq$  24 weeks  
128 (allowing time for viral load and HbeAg testing and return of results prior to initiation of  
129 tenofovir treatment between 28-32 weeks' gestation), 2) intention to continue care at one of two  
130 maternity centers throughout the pregnancy and postpartum period, and 3) not sick enough to be  
131 hospitalized. Written informed consent was obtained in the participant's preferred language  
132 (French or Lingala). At the time of the study, underage pregnant women (<18 years) were  
133 considered emancipated minors in the DRC and were allowed to consent directly without  
134 parental consent.

135 At the time of consent, a structured questionnaire was administered to collect information on  
136 demographic and clinical characteristics. All women were followed through 24 weeks  
137 postpartum, when they completed an exit questionnaire that assessed the acceptability of study  
138 procedures.

139 All participants underwent venous blood collection at baseline to determine risk status for HBV,  
140 including HBeAg (Abbott ARCHITECT HBeAg assay, Abbott Park, Illinois) and HBV DNA  
141 (Abbott RealTime HBV viral load assay, Abbott Park, Illinois), performed at the National Blood  
142 Transfusion Center and National AIDS Control Program laboratories in Kinshasa, respectively.  
143 Baseline kidney (blood urea nitrogen and creatinine) and liver (aspartate aminotransferase or

144 AST, and alanine aminotransferase or ALT) function was evaluated in all enrolled women.  
145 Women with a viral load  $\geq 200,000$  IU/mL and/or HBeAg positivity were considered at ‘high-  
146 risk’ for HBV MTCT and were further assessed for eligibility for prophylactic treatment with  
147 tenofovir disoproxil fumarate (TDF).<sup>3,15,16</sup> Women with high-risk HBV, without signs of reduced  
148 kidney function (glomerular filtration rate (GFR)  $<50$  mL/min) or abnormal liver function (as  
149 determined by the study physician), were initiated on once daily 300mg dosing of TDF (Gilead  
150 Sciences, South San Francisco, CA) treatment between 28-32 weeks’ gestation and continued  
151 through 12-weeks’ postpartum. We assured that any women with HIV-HBV co-infection were  
152 on a TDF-containing regimen, per national guidelines. Details of additional follow-up  
153 procedures for women with high-risk HBV can be found in the **Supplementary Material**. To  
154 assess TDF adherence, tenofovir diphosphate (TFVdp) levels were measured at the University of  
155 North Carolina’s Eshelman School of Pharmacy using DBS samples collected from high-risk  
156 women at delivery. TFVdp levels represent an average of expected adherence over a several  
157 month period, as the medication has a long half-life in red blood cells. TFVdp concentrations in  
158 DBS of 490, 980 and 1750 fmol/punch indicated a participant taking 2, 4 and 7 doses per week,  
159 respectively, based on an expected 1.4-fold bias in concentrations from published thresholds.<sup>17</sup>

160 All exposed infants were given a birth-dose of monovalent HBV vaccine (Euvax-B, 0.5 mL), as  
161 soon as possible and ideally within 24 hours of life. The timing of birth and of vaccination were  
162 recorded. Infants were monitored for at least 24 hours after receipt of vaccine, and adverse  
163 reactions were recorded. Infants underwent point-of-care HBsAg testing at 24 weeks.

#### 164 *Measures and Statistical Analysis*

165 Feasibility was the key part of the program that was evaluated: the feasibility of screening  
166 pregnant women to identify those at high risk for HBV MTCT and to provide them with antiviral

167 prophylaxis, and the feasibility of administering the birth-dose vaccine to infants of women with  
168 HBV.

169 To assess the feasibility of viral prophylaxis for women at high risk of HBV MTCT, we  
170 calculated the following proportions: 1) women who tested positive by HbsAg screening, 2)  
171 HBsAg+ women who consented for enrollment, 3) eligible women with high-risk HBV who  
172 accepted TDF prophylaxis, and 4) women on TDF who adhered to treatment as measured by a)  
173 pill count, b) viral suppression at delivery (defined as HBV viral load < 200,000 IU/mL), and c)  
174 TFVdp level. Acceptability of the program was assessed by calculating frequencies of aggregate  
175 responses on the exit questionnaire. A predetermined cutoff of 80% reporting the program to be  
176 “very acceptable” or “somewhat acceptable” on survey responses was deemed “acceptable”.

177 Secondly, we evaluated the safety of TDF prophylaxis by screening for adverse events, and  
178 the percentage of women who developed ALT elevation during/after antiviral treatment.  
179 Timeliness of birth-dose vaccination was calculated as the proportion of infants who received  
180 birth-dose vaccine within 24 hours of life. The incidence of HBV MTCT (the proportion of  
181 infants who tested positive for HBsAg at 24 weeks) was calculated. Finally, we calculated the  
182 proportion of women who were lost-to-follow-up (LTFU) by delivery and by 24 weeks’  
183 postpartum.

184 Demographics of enrolled women were analyzed from the enrollment questionnaire. A principal  
185 component analysis was used to combine household attributes into a wealth index similar to  
186 other Kinshasa-based studies (**Supplementary Material**).<sup>18</sup> Statistical computations were  
187 carried out using R 4.0.3 (R Core Team, Vienna, Austria).



188 Institutional Review Board approval was obtained from the University of North Carolina at  
189 Chapel Hill (#17-2090) and the Kinshasa School of Public Health (CE/ESP/001/2018) prior to  
190 initiation of the study. The trial is registered at ClinicalTrials.gov (NCT03567382).

191

## 192 **RESULTS**

### 193 *Maternal HBV prevalence and high-risk disease*

194 Of 4,016 pregnant women screened for HBV, 109 were HBsAg-positive, indicating an overall  
195 HBsAg prevalence of 2.7% (95% CI: 2.2%-3.2%). A total of 91 women met eligibility criteria;  
196 all provided informed consent and were enrolled. Enrollment and results across the care  
197 continuum are displayed in **Figure 1**. One woman was withdrawn from the treatment program  
198 due to a false pregnancy (study staff confirmed a negative urine pregnancy test despite report of  
199 pregnancy by the woman); data from 90 women were therefore included. The median age of  
200 enrolled women was 31 (IQR: 25,34) years and the median gestational age was 19 weeks (IQR:  
201 15,22) (**Table 1**). Only one woman was co-infected with HIV and HBV; she received a TDF-  
202 based antiretroviral regimen. Reasons women elected not to enroll are shown in **Figure 2**. Of the  
203 90 women, ten (11.1%) had high-risk HBV; nine of ten were HBeAg positive and five of ten had  
204 a high viral load. Women with high-risk HBV were younger and presented later in pregnancy  
205 than women without high-risk HBV (**Table 1**).

### 206 *Retention in care through delivery and 24-weeks' postpartum*

207 Three women voluntarily withdrew and 12 were lost-to-follow-up by the time of the delivery  
208 visit. Eleven women voluntarily withdrew by 24-weeks' postpartum, three women did not have  
209 living children (two miscarriages and one stillbirth), one infant died, and 21 women were lost-to-

210 follow-up despite repeated efforts by the study team to contact them by telephone or in person  
211 (**Figure 2**). Thus, 54 women (60·0%) completed the study through the 24-week postpartum visit.  
212 Of the ten women with high-risk HBV, six (60·0%) were followed to study completion. Two  
213 women with high-risk HBV voluntarily withdrew from the study; the first prior to initiation of  
214 TDF, and the second after delivery. A third woman moved to another province in the DRC after  
215 delivery, and a fourth was lost to follow-up (LTFU) after the 10-week visit.

#### 216 *Infant vaccination and MTCT*

217 A total of 88 infants were born to enrolled women. Overall, sixty of 88 infants (68·2%) received  
218 a birth-dose of monovalent HBV vaccine; of these, 46 (76·7%) received a timely birth-dose  
219 within 24 hours. Among 63 infants born at the two study facilities, 48 (76·2%) received a birth-  
220 dose, and 41 of 48 (85·4%) were timely. Among 25 infants born at an outside facility, 12  
221 (48·0%) received a birth-dose, and five of 12 (41·7%) were timely. None of the infants were born  
222 outside of a health facility. **Figure 1B** depicts the care continuum for infants, including reasons  
223 for missed or untimely vaccination. No adverse events were reported related to the birth-dose. Of  
224 53 infants tested at 24 weeks, zero (0%) tested positive for HBsAg, consistent with no HBV  
225 MTCT.

#### 226 *TDF adherence and viral suppression*

227 Nine of ten (90·0%) women with high-risk HBV were initiated on TDF. One woman refused  
228 therapy and withdrew from the study. Five of nine (55·6%) women achieved viral suppression  
229 (<200,000 IU/mL) on TDF therapy by the time of delivery (**Figure 1A**); the remaining four  
230 women had decreased viral loads from enrollment to delivery, but not below 200,000 IU/mL  
231 (**Figure 3**). While all women taking TDF returned empty pill bottles and reported full adherence  
232 per the exit survey, TFVdp levels suggested low adherence. Three of nine women delivered

233 within 28 days of initiation of TDF therapy, so TFVdp cannot be interpreted. Of the remaining  
234 six, three women had levels below the limit of quantification (BLQ), and one each with levels  
235 reflecting <2 doses per week, 2-4 doses per week, and 4-7 doses per week (**Figure 3**). All three  
236 women with detectable TFVdp who initiated TDF therapy >28 days prior to delivery were virally  
237 suppressed at delivery (**Figure 3**).

#### 238 *TDF safety*

239 There were no serious adverse events associated with TDF. One woman reported dizziness while  
240 taking the medication; otherwise, no side effects were reported. Three women (33.3%)  
241 developed rebound elevations of ALT (**Supplementary Figure 1**), and two women (22.2%)  
242 developed corresponding elevations of HBV DNA after stopping TDF at 12-weeks' postpartum.  
243 These women were referred to the study gastroenterologist for further management, but none  
244 attended their appointments.

#### 245 *Acceptability of program procedures*

246 All seven high-risk women followed through six months reported the act of taking TDF as “very  
247 acceptable”. Forty-eight of 54 women (88.9%) followed through 24-weeks' postpartum reported  
248 having their blood drawn as “very acceptable,” with only two women reporting this as “very” or  
249 “somewhat unacceptable” (**Figure 4**). Only four women reported the infant blood draw as  
250 “somewhat” or “very unacceptable”. Only one woman (1.9%) reported vaccination of her infant  
251 as “very unacceptable”.

252

## 253 **DISCUSSION**

254 We demonstrate the feasibility of implementing a PMTCT of HBV program in the DRC using  
255 existing HIV PMTCT and EPI infrastructure with a two-pronged approach: 1) screening and  
256 treatment of HBV-positive pregnant women at high-risk for MTCT, and 2) provision of a birth-  
257 dose vaccine to HBV-exposed infants. Of the 53 HBV-exposed infants followed through 24  
258 weeks, none were positive for HBV, indicating no vertical transmission. Even with vaccination,  
259 the estimated risk of MTCT among infants born to women with high-risk HBV ranges from 20%  
260 in Asia to 32% in Africa, compared to less than 1% for vaccinated infants born to Asian and  
261 African women without high-risk features.<sup>19</sup> This evidence prompted the WHO to revise HBV  
262 PMTCT guidelines in 2020 to add antiviral prophylaxis to the recommended three-dose  
263 vaccination, with the first dose within 24 hours of life.<sup>3</sup> Our successful integration of HBV  
264 screening of pregnant women and provision of TDF prophylaxis within an existing HIV  
265 PMTCT program in the two busiest maternity centers in Kinshasa is evidence to support the  
266 feasibility of this WHO recommendation, even in the most resource-limited settings.

267

268 The prevalence of HBV among pregnant women in this study was in line with similar studies in  
269 African settings.<sup>19,20</sup> We found that 11.1% of HBV-positive women met criteria for TDF therapy  
270 based on high viral load and/or HBeAg positivity, a percentage that is similar to other reports in  
271 SSA.<sup>20-22</sup> The assessment of high-risk HBV and administration of TDF was feasible within this  
272 study's framework, but without reliable point-of-care tests for HBV DNA quantification or  
273 HbeAg testing, scale-up will be a challenge. Until such infrastructure is in place, HBV birth-dose  
274 should be prioritized as a prevention tool.<sup>23-25</sup>

275

276 Birth-dose vaccination was feasible in two high-volume maternity centers in urban Kinshasa,  
277 DRC, and was largely acceptable to mothers. While we did not achieve vaccination within 24  
278 hours of birth for all infants, this feasibility study demonstrates that a higher standard-of-care is  
279 within reach in the DRC. We identified several barriers to timely administration of the birth-dose  
280 that must be overcome as the country moves to universal birth-dose vaccination. First, many  
281 women delivered at outside facilities rather than at one of the two study facilities. Potential  
282 reasons for delivering at outside facilities include personal preference, cost, quality of care  
283 received and/or need for C-section delivery (which was not possible at either maternity hospital  
284 in the present study). With the adoption of a universal HBV birth-dose vaccine, all facilities  
285 would have access such that maternal preference of delivery site would not determine whether  
286 the infant is vaccinated. Second, baseline knowledge of HBV was limited among mothers in our  
287 study (unpublished data), and dropouts along the care cascade were relatively high. Our team has  
288 previously shown that a mother's perception of HIV risk to her infant was a key determinant of  
289 her retention in the HIV PMTCT care cascade.<sup>26</sup> Third, reliable cold chains are needed. With  
290 support from Gavi and the DRC EPI, established cold chains for other routine vaccines could be  
291 strengthened and used for HBV birth-dose vaccine. At the same time, sentinel studies have  
292 already evaluated storage of HBV birth-dose vaccine outside of the cold chain.<sup>27</sup> Finally, many  
293 births occur outside of health facilities in the DRC and throughout SSA. Initial roll-out to health  
294 centers could be followed by decentralized vaccination after home birth, although the logistics of  
295 this strategy are more complex. Nonetheless, with small investments of resources to strengthen  
296 the existing EPI infrastructure in the DRC, timely delivery of the HBV birth-dose is possible  
297 alongside other birth-dose vaccinations.<sup>28</sup>

298

299 We uncovered a discordance between verbally reported adherence to TDF therapy and adherence  
300 as measured by TFVdp levels. Only three of nine women had TFVdp levels suggesting that they  
301 took at least two doses per week; two of these three women had viral load suppression at  
302 delivery. This is in contrast to the nearly 100% adherence reported on exit surveys and via pill  
303 counts (only empty bottles were returned). Changes in viral load and creatinine among women  
304 taking TDF can be used as proxy measures of adherence but do not fully explain the discordance.  
305 Further studies are needed to understand the drivers of poor adherence.

306

307 The strength of this study lies in its pragmatic, comprehensive approach. In line with recent  
308 WHO guidelines for preventing HBV MTCT, we integrated HbsAg screening into an existing  
309 HIV PMTCT program, leveraged laboratory infrastructure to identify and treat pregnant women  
310 with high-risk HBV, and leveraged the existing EPI cold chain infrastructure to deliver birth-  
311 dose vaccination to exposed infants. This package of interventions is delivered routinely to  
312 prevent HBV MTCT in the Global North, but not in Africa. We longitudinally followed HBV-  
313 infected women and their exposed infants through 24 weeks' postpartum to document adherence  
314 to the cascade of care, side effects of birth-dose vaccine and TDF, and incidence of MTCT.  
315 While most studies of HBV MTCT in Africa published to-date focus on HBV-HIV co-infection,  
316 our cohort of mainly HBV mono-infected pregnant women is generalizable to settings in Africa  
317 where HIV prevalence is low.

318

319 This study also had limitations. First, the sample size was relatively small. Yet, to the best of our  
320 knowledge, this is the largest study of PMTCT of HBV among mono-infected pregnant women  
321 in SSA performed to-date. Second, the absence of a control group prevented us from quantifying

322 the effectiveness of specific interventions. We were ethically obligated to provide effective HBV  
323 prevention measures; other studies in African settings have described the natural history of  
324 chronic HBV.<sup>29</sup> Third, we observed a high rate of LTFU in this study. While LTFU negatively  
325 impacts our ability to determine incidence of MTCT, it is an expected feature of pragmatic  
326 feasibility studies and consistent with postnatal follow-up patterns in the DRC.<sup>18</sup> Fourth, supply  
327 chain disruption prevented us from completing planned laboratory comparisons of HBeAg and  
328 viral load testing on DBS versus venous blood in-country. The COVID-19 pandemic bears some  
329 responsibility for these challenges, but nascent HBV laboratory reagent supply chains are also to  
330 blame. Delays in the return of laboratory results to some participants may have contributed to  
331 withdrawal or LTFU. Unanticipated stockouts led to a lack of HBeAg results for three women at  
332 enrollment; all three women were classified as low-risk for HBV MTCT based on their low viral  
333 loads. Finally, the measurement of TFVdp levels from DBS may not accurately depict adherence  
334 to TDF therapy. TFVdp is not sensitive for behavior change, as it represents an average of  
335 adherence over several months. Furthermore, we cannot exclude the possibility of TFVdp  
336 degradation during DBS preparation or transportation from the DRC, where ambient  
337 temperatures and humidity are high. There is no clear threshold for how much tenofovir is  
338 required to prevent HBV MTCT, but decreases in maternal HBV DNA prior to delivery are  
339 associated with decreased risk of HBV MTCT.<sup>6,7</sup> Despite variable TFVdp levels, most women  
340 did have a several log decline in HBV DNA. Even with these limitations, we successfully  
341 implemented effective HBV PMTCT measures.

342

343 In conclusion, this study provides strong evidence in support of the WHO recommendation that  
344 mother-to-infant HBV transmission can be prevented by building upon HIV PMTCT and EPI

345 platforms in resource-constrained settings such as the DRC. Lessons learned from HIV PMTCT,  
346 including how to improve retention and adherence to prophylaxis, can be leveraged to address  
347 similar challenges in the HBV PMTCT program. Deploying a package of proven interventions  
348 used routinely in the Global North but not widely adopted in Africa, we demonstrate the  
349 feasibility of HBV MTCT prevention measures during routine care at two high-volume maternity  
350 hospitals in Kinshasa. A two-pronged maternal screening/treatment and infant birth-dose  
351 approach was acceptable to mothers, and no cases of HBV MTCT were observed. Though  
352 obstacles must be overcome before roll-out of antiviral prophylaxis for pregnant women at high-  
353 risk of HBV MTCT, universal birth-dose HBV vaccination is a proven measure that should be  
354 implemented in the DRC and throughout SSA. To meet WHO elimination goals by 2030,<sup>30</sup>  
355 countries with endemic HBV such as the DRC should adopt and implement WHO guidelines that  
356 establish pathways for HBV PMTCT,<sup>3</sup> and should prioritize cross-cutting HBV prevention  
357 measures that include birth-dose vaccination.



358 **NOTES**

359 *Contributors.* PT, JBP, RJ, MY and SRM designed the study. PT wrote the first draft, with  
360 contributions from CEM, MY and JBP. KM, NR, BK, MF, MT, PN, PM and CM contributed to  
361 field work. CEM, PT, and JBP analyzed the data. All authors edited and revised the final  
362 manuscript and approve it in its final version.

363

364 *Declarations of interest.* GC is an employee and shareholder of Abbott Laboratories. PT  
365 received support from an ASTMH/Burroughs-Wellcome Fund award. JBP and PT report  
366 research support from Gilead Sciences; JBP also reports research support from the World Health  
367 Organization, and honoraria from Virology Education. All other authors report no potential  
368 conflicts.

369

370 *Acknowledgements.* This project was supported by a Gillings Innovation Laboratory award  
371 funded by the 2007 Gillings Gift to UNC-Chapel Hill's Gillings School of Global Public Health.  
372 Abbott Laboratories provided HBV reagents free-of-charge for this study. The HIV PMTCT  
373 study whose infrastructure was leveraged for this project was supported by a grant from the  
374 National Institute of Health (NICHD R01HD087993). TFVdp testing was performed by the  
375 UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, an NIH  
376 funded program (P30AI050410). PT is supported by a grant from the National Institute of Health  
377 (NIAID K08AI148607). CEM received support from a grant from the National Institute of  
378 Health (NIGMS T32GM008719).

379

380 We would like to thank all of the women who participated in this study. We also acknowledge  
381 the staff at the maternity clinics, as well as provincial and national health authorities. We are  
382 grateful for the support we have received from administrative staff at the University of North  
383 Carolina and at Kinshasa School of Public Health. We also thank David Wohl for helpful advice  
384 and and the UNC Clinical Pharmacology and Analytical Chemistry Core for supporting the  
385 TFVdp assays. We grieve the loss of Professor Steven Meshnick, who played a major role in this  
386 study and whose vision and mentorship were critical to its success.

387

388 ***Data Sharing Statement.*** Datasets will not be made publicly available because they contain  
389 protected health information. However, the authors will share de-identified participant data,  
390 alongside the study protocol, statistical analysis plan and analytic code, upon reasonable request  
391 and with approval by an independent review committee (“learned intermediary”).

392

393

394

395

396

397

398

399

400

401

402

403

404

405 **REFERENCES**

- 406 1. World Health Organization. Global Hepatitis Report, 2017.  
407 [http://www.who.int/libproxy.lib.unc.edu/hepatitis/publications/global-hepatitis-](http://www.who.int/libproxy.lib.unc.edu/hepatitis/publications/global-hepatitis-report2017/en/)  
408 [report2017/en/](http://www.who.int/libproxy.lib.unc.edu/hepatitis/publications/global-hepatitis-report2017/en/) Accessed 21 July 2020.
- 409 2. Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission  
410 of hepatitis B virus and hepatitis C virus. *Expert Review of Anti-infective Therapy*.  
411 2014;12(7):775-782.
- 412 3. WHO Guidelines Approved by the Guidelines Review Committee. In: *Prevention of*  
413 *Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in*  
414 *Pregnancy*. Geneva: World Health Organization  
415 © World Health Organization 2020.; 2020.
- 416 4. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to  
417 passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. *J Viral*  
418 *Hepat*. 2012;19(2):e18-25.
- 419 5. Schillie S, Walker T, Veselsky S, et al. Outcomes of infants born to women infected with  
420 hepatitis B. *Pediatrics*. 2015;135(5):e1141-1147.
- 421 6. Pan CQ, Duan Z, Dai E, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers  
422 with High Viral Load. *N Engl J Med*. 2016;374(24):2324-2334.
- 423 7. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in  
424 interrupting mother-to-infant transmission of hepatitis B virus. *Hepatology*.  
425 2015;62(2):375-386.
- 426 8. Thompson P, Parr JB, Holzmayer V, et al. Seroepidemiology of Hepatitis B in the  
427 Democratic Republic of the Congo. *Am J Trop Med Hyg*. 2019;101(1):226-229.
- 428 9. UNICEF. At a glance: Congo Statistics.  
429 [https://www.unicef.org/infobycountry/congo\\_statistics.html](https://www.unicef.org/infobycountry/congo_statistics.html). Published 2013. Updated 24  
430 December 2013. Accessed August 22, 2019.
- 431 10. WHO vaccine-preventable diseases: monitoring system. 2018 global summary.  
432 [http://apps.who.int/immunization\\_monitoring/globalsummary/schedules](http://apps.who.int/immunization_monitoring/globalsummary/schedules). Updated 22  
433 October 2018. Accessed February 18, 2019.
- 434 11. Spearman CW, Afihene M, Ally R, et al. Hepatitis B in sub-Saharan Africa: strategies to  
435 achieve the 2030 elimination targets. *The Lancet Gastroenterology & Hepatology*.  
436 2017;2(12):900-909.
- 437 12. Andersson MI, Rajbhandari R, Kew MC, et al. Mother-to-child transmission of hepatitis B  
438 virus in sub-Saharan Africa: time to act. *The Lancet Global Health*. 2015;3(7):e358-e359.
- 439 13. Yotebieng M, Behets F, Kawende B, Ravelomanana NLR, Tabala M, Okitolonda EW.  
440 Continuous quality improvement interventions to improve long-term outcomes of  
441 antiretroviral therapy in women who initiated therapy during pregnancy or breastfeeding  
442 in the Democratic Republic of Congo: design of an open-label, parallel, group  
443 randomized trial. *BMC Health Serv Res*. 2017;17(1):306.
- 444 14. Mpody C, Thompson P, Tabala M, et al. Hepatitis B infection among pregnant and post-  
445 partum women living with HIV and on antiretroviral therapy in Kinshasa, DR Congo: A  
446 cross-sectional study. *PLoS one*. 2019;14(5):e0216293-e0216293.
- 447 15. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic  
448 hepatitis B. *Hepatology*. 2016;63(1):261-283.

- 449 16. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J*  
450 *Hepatol.* 2012;57(1):167-185.
- 451 17. Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular Tenofovir-Diphosphate and  
452 Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.  
453 *Antimicrobial Agents and Chemotherapy.* 2018;62(1):e01710-01717.
- 454 18. Yotebieng M, Mpody C, Ravelomanana NL, et al. HIV viral suppression among pregnant  
455 and breastfeeding women in routine care in the Kinshasa province: a baseline evaluation  
456 of participants in CQI-PMTCT study. *J Int AIDS Soc.* 2019;22(9):e25376.
- 457 19. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of  
458 mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Aliment*  
459 *Pharmacol Ther.* 2016;44(10):1005-1017.
- 460 20. Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B  
461 control in the African region. *Pan Afr Med J.* 2017;27(Suppl 3):17.
- 462 21. Noubiap JJ, Nansseu JR, Ndoula ST, Bigna JJ, Jingi AM, Fokom-Domgue J.  
463 Prevalence, infectivity and correlates of hepatitis B virus infection among pregnant  
464 women in a rural district of the Far North Region of Cameroon. *BMC Public Health.*  
465 2015;15:454.
- 466 22. Okoth F, Mbutia J, Gatheru Z, et al. Seroprevalence of hepatitis B markers in pregnant  
467 women in Kenya. *East Afr Med J.* 2006;83(9):485-493.
- 468 23. Klingler C, Thoumi A, Mrithinjayam V. Cost-effectiveness analysis of an additional birth-  
469 dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in  
470 Mozambique. *Vaccine.* 2012;31.
- 471 24. Memirie ST, Desalegn H, Naizgi M, et al. Introduction of birth-dose of hepatitis B virus  
472 vaccine to the immunization program in Ethiopia: an economic evaluation. *Cost Eff*  
473 *Resour Alloc.* 2020;18:23-23.
- 474 25. Dionne-Odom J, Njei B, Tita ATN. Elimination of Vertical Transmission of Hepatitis B in  
475 Africa: A Review of Available Tools and New Opportunities. *Clin Ther.* 2018;40(8):1255-  
476 1267.
- 477 26. Yotebieng M, Moracco KE, Thirumurthy H, et al. Conditional Cash Transfers Improve  
478 Retention in PMTCT Services by Mitigating the Negative Effect of Not Having Money to  
479 Come to the Clinic. *J Acquir Immune Defic Syndr.* 2017;74(2):150-157.
- 480 27. Breakwell L, Anga J, Dadari I, Sadr-Azodi N, Ogaoga D, Patel M. Evaluation of storing  
481 hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying  
482 opportunities and barriers to implementation. *Vaccine.* 2017;35(21):2770-2774.
- 483 28. Zivich PN, Kiketa L, Kawende B, Lapika B, Yotebieng M. Vaccination Coverage and  
484 Timelines Among Children 0-6 Months in Kinshasa, the Democratic Republic of Congo:  
485 A Prospective Cohort Study. *Matern Child Health J.* 2017;21(5):1055-1064.
- 486 29. Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in  
487 West Africa: a longitudinal population-based study from The Gambia. *Gut.*  
488 2016;65(12):2007-2016.
- 489 30. World Health Organization. Global health sector strategy on viral hepatitis, 2016-2021:  
490 Towards ending viral hepatitis.  
491 [http://apps.who.int.libproxy.lib.unc.edu/iris/bitstream/10665/246177/1/WHO-HIV-](http://apps.who.int/libproxy.lib.unc.edu/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf)  
492 [2016.06-eng.pdf](http://apps.who.int/libproxy.lib.unc.edu/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf). Accessed January 8, 2018.
- 493

494

**Table 1. Characteristics of the study population, by high- and low-risk HBV infection\***

		<b>Overall</b>	<b>Low-risk</b>	<b>High-risk</b>	<b>p-value†</b>
Total, n		90	80	10	
Age, median years (IQR)		31 (25, 34)	31 (26, 34)	24 (20, 25)	0.003
Median gestational age, weeks (IQR)		19 (15, 22)	19 (13, 20)	21 (20, 23)	0.025
Prior HBV diagnosis, n (%)	No	82 (91.1)	72 (90.0)	10 (100.0)	0.590
	Yes	8 (8.9)	8 (10.0)	0 (0.0)	
Total pregnancies, n (%)	1	16 (17.8)	14 (17.5)	2 (20.0)	0.311
	2	18 (20.0)	13 (16.2)	5 (50.0)	
	3	18 (20.0)	17 (21.2)	1 (10.0)	
	4	14 (15.6)	13 (16.2)	1 (10.0)	
	5	10 (11.1)	10 (12.5)	0 (0.0)	
	≥6	14 (15.6)	13 (16.2)	1 (10.0)	
Living children, n (%)	0	28 (31.1)	21 (26.2)	7 (70.0)	0.099
	1	16 (17.8)	15 (18.8)	1 (10.0)	
	2	18 (20.0)	18 (22.5)	0 (0.0)	
	3	12 (13.3)	11 (13.8)	1 (10.0)	
	4	16 (17.8)	15 (18.8)	1 (10.0)	
Adults in household, n (%)	0	2 (2.2)	2 (2.5)	0 (0.0)	0.770
	1	24 (26.7)	22 (27.5)	2 (20.0)	
	2	31 (34.4)	26 (32.5)	5 (50.0)	
	3-4	25 (27.8)	22 (27.5)	3 (30.0)	
	≥5	8 (8.9)	8 (10.0)	0 (0.0)	
Children in household, n (%)	0	22 (24.4)	17 (21.2)	5 (50.0)	0.224
	1-2	32 (35.6)	31 (38.8)	1 (10.0)	
	2-3	25 (27.8)	22 (27.5)	3 (30.0)	
	5-10	10 (11.1)	9 (11.2)	1 (10.0)	
	>10	1 (1.1)	1 (1.2)	0 (0.0)	
Marital status, n (%)	Married or living in a marriage-like relationship	83 (92.2)	74 (92.5)	9 (90.0)	0.345
	Separated	1 (1.1)	1 (1.2)	0 (0.0)	
	Divorced	1 (1.1)	1 (1.2)	0 (0.0)	
	Never married	4 (4.4)	4 (5.0)	0 (0.0)	
	Missing	1 (1.1)	0 (0.0)	1 (10.0)	
Highest schooling, n (%)	Never attended school	4 (4.4)	4 (5.0)	0 (0.0)	0.293
	Primary	2 (2.2)	1 (1.2)	1 (10.0)	


	Secondary	64 (71.1)	58 (72.5)	6 (60.0)	
	Higher education	20 (22.2)	17 (21.2)	3 (30.0)	
Wealth quartile, n (%)‡	Lowest	23 (25.6)	22 (27.5)	1 (10.0)	0.098
	Lower-middle	22 (24.4)	20 (25.0)	2 (20.0)	
	Upper-middle	22 (24.4)	21 (26.2)	1 (10.0)	
	Highest	23 (25.6)	17 (21.2)	6 (60.0)	
	Market/street trader	37 (62.7)	35 (63.6)	2 (50.0)	0.270
Occupation, n (%)	Seamstress	5 (8.5)	4 (7.3)	1 (25.0)	
	Hairdresser	6 (10.2)	5 (9.1)	1 (25.0)	
	Salaried	10 (16.9)	10 (18.2)	0 (0.0)	
	Other	1 (1.7)	1 (1.8)	0 (0.0)	
	Someone else	13 (22.0)	12 (21.8)	1 (25.0)	1.000
Employer, n (%)	Self-employed	46 (78.0)	43 (78.2)	3 (75.0)	

\*High-risk infection defined as HBV viral load  $\geq 200,000$  IU/mL and/or HBeAg positivity.


†Wilcoxon rank-sum test was used to compare continuous data. Fisher's exact test was used to compare categorical data.

‡Wealth quartiles were calculated from a principal component analysis including the following variables: people per household room, number of beds in household, number of radios in household, number of televisions in household, number of phones in household, number of refrigerators in household, ownership of a car, presence/absence of electricity in household, cooking with electricity, cooking with wood, and private water source.

### A: Care continuum of women



### B: Care continuum of infants







Figure 2: Flowsheet of screened women and reasons for not enrolling






**Figure 3. Viral loads of women with high-risk disease across study timepoints by tenofovir diphosphate (TFVdp) level.** TFVdp levels reflect average adherence over several months.

\*Imputed viral load from dried blood spot assay (see Supplementary Materials).

\*\* Tenofovir disoproxil fumarate initiated within 28 days of delivery, before TFVdp steady-state is expected.



**Figure 4. Acceptability of clinical study components assessed at 6-month follow-up visit (n=54)**